TRELSTAR (R) is currently available in a 4-week depot formulation (TRELSTAR (R) DEPOT) and a 12-week long-acting formulation (TRELSTAR (R) LA), offering an alternative treatment for prostate cancer ...

Patients participating in clinical trials reported that TRELSTAR (R) administration was well tolerated, with a low incidence of injection site pain. Important Safety Information In clinical trials, ...

March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...

Watson Pharmaceuticals has received FDA approval of Trelstar (triptorelin pamoate for injectable suspension) 22.5 mg, the first and only six-month intramuscular gonadotropin releasing hormone (GnRH) ...